1. Volume 380, Issue 9849, Pages 1250-1258 (October 2012)
Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis 
Ravindra K Gupta, MRCP, Michael R Jordan, MD, Binta J Sultan, MRCP, Andrew Hill, PhD, Daniel HJ Davis, MRCP, John Gregson, MSc, Anthony W Sawyer, PhD, Raph L Hamers, MD, Nicaise Ndembi, PhD, Prof Deenan Pillay, FRCP, Dr Silvia Bertagnolio, MD 
The Lancet 
Volume 380, Issue 9849, Pages (October 2012)
DOI: /S (12)
Copyright © 2012 Elsevier Ltd Terms and Conditions

2. Figure 1 Countries contributing data by regions and subregions
The Lancet  , DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions

3. Figure 2 Study selection
The Lancet  , DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions

4. Figure 3
Prevalence of drug resistance in treatment-naive trial participants with HIV-1, by time since antiretroviral rollout
(A) East Africa. (B) Southern Africa. (C) West and central Africa. (D) Latin America and the Caribbean. Every circle is a study and the size of the circle is proportional to the precision of the estimate from the individual study, with sizes comparable within individual graphs only. The trend line is predicted prevalence.
The Lancet  , DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions

5. Figure 4
Prevalence of major drug-resistance mutations that confer resistance to non-nucleoside reverse transcriptase inhibitors, by time since antiretroviral rollout in east Africa
Size of circle is proportional to the precision of the estimate from the individual study, with sizes comparable within individual graphs only. The trend line is predicted prevalence. DRM=drug-resistance mutation. NNRTI=non-nucleoside reverse transcriptase inhibitor.
The Lancet  , DOI: ( /S (12) )
Copyright © 2012 Elsevier Ltd Terms and Conditions